The key to cerebral infarction prevention lies in the diagnosis of the etiology of cerebral infarction and the recognition of risk factors. Physicians should make full use of the available screening tools with evidence-based medical evidence to conduct a comprehensive risk assessment and etiological diagnosis of patients, stratify patients with different risk of recurrence for different etiologies and develop targeted and individualized treatment plans according to the number and severity of risk factors. Strategies for cerebral infarction prevention include: 1. search for and removal of risk factors, 2. antithrombotic therapy (cardiogenic: anticoagulant; noncardiogenic: antiplatelet). Non-cardiogenic cerebral infarction prophylaxis includes six elements: three cornerstones of which: antiplatelet, statin, and antihypertensive, and three concepts: stratification, long-term, and adherence to guidelines. Firstly, patients can remove controllable risk factors on their own, such as smoking, over-salty diet, heavy alcohol consumption, and irritable and agitated mood. In patients with non-cardiogenic embolic ischemic stroke or TIA, antiplatelet agents are recommended in most cases to prevent recurrence of ischemic stroke/TIA, except in a few cases where anticoagulation is required. 1. The choice of antiplatelet agents is based on monotherapy. Clopidogrel (75 mg/d) and aspirin (50-325 mg/d) can be the drugs of choice. There is evidence that clopidogrel is superior to aspirin, with more significant benefit especially for high-risk patients. 2. Dual antiplatelet agents are not recommended for routine application. However, in patients with acute coronary artery disease (e.g., unstable angina, Q-wave-free myocardial infarction) or recent stenting, the combination of clopidogrel + aspirin is recommended. For ischemic stroke and TIA, antihypertensive therapy is recommended to reduce the risk of recurrence of stroke and other vascular events. With reference to advanced age, basal blood pressure, usual medication, and tolerability, the antihypertensive goal should generally be ≤140 mmHg.